I expect some off-label reimbursement for spasticity patients because it's in the interest of third-party payers to cover Daxxify if priced at parity to Botox. If there were no other bonts approved for spasticity, it would be a different story.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”